Advances in treating bronchopulmonary dysplasia

References

• Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723–1729.
   PubMedGoogle Scholar
• Steinhorn R, Davis JM, Gopel W, et al. Chronic pulmonary insufficiency of prematurity: developing optimal endpoints for drug development. J Pediatr. 2017;191:15–21.
   PubMed Web of Science ®Google Scholar
• Greenough A. Long-term respiratory consequences of premature birth at less than 32 weeks of gestation. Early Hum Dev. 2013;89:S25–27.
   PubMed Web of Science ®Google Scholar
• Greenough A. Long-term pulmonary outcome in the preterm infant. Neonatology. 2008;93:324–327.
   PubMed Web of Science ®Google Scholar
• Guaman MC, Gien J, Baker CD, et al. Point prevalence, clinical characteristics, and treatment variation for infants with severe bronchopulmonary dysplasia. Am J Perinatol. 2015;32:960–967.
   PubMed Web of Science ®Google Scholar
• Hunt KA, Dassios T, Ali K, et al. Prediction of bronchopulmonary dysplasia development. Arch Dis Child Fetal Neonatal Ed. 2018;103:F598–F599.
   PubMed Web of Science ®Google Scholar
• Peng W, Zhu H, Shi H, et al. Volume-targeted ventilation is more suitable than pressure-limited ventilation for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2014;99:F158–165.
   PubMed Web of Science ®Google Scholar
• Hunt K, Dassios T, Ali K, et al. Volume targeting levels and work of breathing in infants with evolving or established bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed. 2019 Jan; 104(1): F46-F49. [Epub ahead of print 2018].
   Web of Science ®Google Scholar
• Keszler M, Nassabeh-Montazami S, Abubakar K. Evolution of tidal volume requirement during the first 3 weeks of life in infants <800 g ventilated with volume guarantee. Arch Dis Child Fetal Neonatal Ed. 2009;94:F279–282.
   PubMed Web of Science ®Google Scholar
• Schulze A. Respiratory mechanical unloading and proportional assist ventilation in infants. Acta Paediatr Suppl. 2002;91:19–22.
   PubMedGoogle Scholar
• Schulze A, Rieger-Fackedley E, Gerhardt T, et al. Randomised crossover comparison of proportional assist ventilation and patient triggered ventilation in extremely low birth weight infants with evolving chronic lung disease. Neonatology. 2007;92:1–7.
   PubMed Web of Science ®Google Scholar
• Bhat P, Patel DS, Hannam S, et al. Crossover study of proportional assist versus assist control ventilation. Arch Dis Child Fetal Neonatal Ed. 2015;100:F35–38.
   PubMed Web of Science ®Google Scholar
• Shetty S, Bhat P, Hickey A, et al. Proportional assist versus assist control ventilation in premature infants. Eur J Pediatr. 2016;175:57–61.
   PubMed Web of Science ®Google Scholar
• Navalesi P, Longhini F. Neurally adjusted ventilatory assist. Curr Opin Crit Care. 2015;21:58–64.
   PubMed Web of Science ®Google Scholar
• Jung YH, Kim HS, Lee J, et al. neurally adjusted ventilatory assist in preterm infants with established or evolving bronchopulmonary dysplasia on high-intensity mechanical ventilatory support: A single-center experience. Pediatr Crit Care Med. 2016;17:1142–1146.
   PubMed Web of Science ®Google Scholar
• Shetty S, Hunt K, Peacock J, et al. Crossover study of assist control ventilation and neurally adjusted ventilatory assist. Eur J Pediatr. 2017;176:509–513.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim HS, Jung YH, et al. Neurally adjusted ventilatory assist for infants under prolonged ventilation. Pediatr Int. 2017;59:540–544.
   PubMed Web of Science ®Google Scholar
• DiBlasi RM, Crotwell DN, Poli J, et al. A pilot study to assess short-term physiologic outcomes of transitioning infants with severe bronchopulmonary dysplasia from ICU to two subacute ventilators. Can J Respir Ther. 2018;54.
   PubMedGoogle Scholar
• Shetty S, Hickey A, Rafferty GF, et al. Work of breathing during CPAP and heated humidified high-flow nasal cannula. Arch Dis Child Fetal Neonatal Ed. 2016;101:F404–407.
   PubMed Web of Science ®Google Scholar
• Szczapa T, Gadzinowski J, Moczko J, et al. Heliox for mechanically ventilated newborns with bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed. 2014;99:F128–F133.
   PubMed Web of Science ®Google Scholar
• Doyle LW, Cheong JL, Ehrenkranz RA, et al. Late (>7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017;10:CD001145.22.
   Google Scholar
• Lim G, Lee BS, Choi YS, et al. Delayed dexamethasone therapy and neurodevelopmental outcomes in preterm infants with bronchopulmonary dysplasia. Pediatr Neonatol. 2015;56:261–267.
   PubMed Web of Science ®Google Scholar
• Harris C, Crichton S, Zivanovic S, et al. Effect of dexamethasone exposure on the neonatal unit on the school age lung function of children born very prematurely. PLoS One. 2018;13:e0200243.
   PubMed Web of Science ®Google Scholar
• Cheong JL, Burnett AC, Lee KJ, et al. Association between postnatal dexamethasone for treatment of bronchopulmonary dysplasia and brain volumes at adolescence in infants born very preterm. J Pediatr. 2014;164:737–743.
   PubMed Web of Science ®Google Scholar
• Onland W, Offringa M, van Kaam A. Late (>7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017;8:CD002311.26.
   PubMedGoogle Scholar
• Slaughter JL, Stenger MR, Reagan PB, et al. Utilisation of inhaled corticosteroids for infants with bronchopulmonary dysplasia. PLoS One. 2014;9:e106838.
   PubMed Web of Science ®Google Scholar
• Onland W, De Jaegera AP, Offringa M, et al. Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017;1:CD010941.
   PubMedGoogle Scholar
• Clouse BJ, Jadcherla SR, Slaughter JL. Systematic review of inhaled bronchodilator and corticosteroid therapies in infants with bronchopulmonary dysplasia: implications and future directions. PLoS One. 2016;11:e0148188.
   PubMed Web of Science ®Google Scholar
• Kugelman A, Peniakov M, Zangen S, et al. Inhaled hydrofluoalkane-beclomethasone dipropionate in bronchopulmonary dysplasia. A double-blind, randomised, controlled pilot study. J Perinatol. 2017;37:197–202.
   PubMed Web of Science ®Google Scholar
• Shah SS, Ohlsson A, Halliday HL, et al. Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2017;10:CD002058.
   PubMedGoogle Scholar
• Slaughter JL, Stenger MR, Reagan PB, et al. Inhaled bronchodilator use for infants with bronchopulmonary dysplasia. J Perinatol. 2015;35:61–66.
   PubMed Web of Science ®Google Scholar
• Yuksel B, Greenough A. Ipratropium bromide for symptomatic preterm infants. Eur J Pediatr. 1991;150:854–857.
   PubMed Web of Science ®Google Scholar
• Yuksel B, Greenough A, Maconochie I. Effective bronchodilator treatment by a simple spacer device for wheezy premature infants. Arch Dis Child. 1990;65:782–785.
   PubMed Web of Science ®Google Scholar
• Ardhanareeswaran K, Mirotsou M. Lung stem and progenitor cells. Respiration. 2013;85:89–95.
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007;357:1841–1854.
   PubMed Web of Science ®Google Scholar
• Rupprecht T, Rupprecht C, Harms D, et al. Leukotriene receptor blockade as a life-saving treatment in severe bronchopulmonary dysplasia. Respiration. 2014;88:285–290.
   PubMed Web of Science ®Google Scholar
• Kim SB, Lee JH, Lee J, et al. The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia. Korean J Pediatr. 2015;58:347–353.
   PubMedGoogle Scholar
• Sehgal A, Krishnamurthy MB, Clark M, et al. ACE inhibition for severe bronchopulmonary dysplasia - an approach based on physiology. Physiol Rep. 2018;6:e13821.
   PubMed Web of Science ®Google Scholar
• Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120:1260–1269.
   PubMed Web of Science ®Google Scholar
• Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol. 2005;67:623–661.
   PubMed Web of Science ®Google Scholar
• Nagiub M, Kanaan U, Simon D, et al. Risk factors for development of pulmonary hypertension in infants with bronchopulmonary dysplasia: systematic review and meta-analysis. Paediatr Respir Rev. 2017;23:27–32.
   PubMed Web of Science ®Google Scholar
• Banks BA, Seri I, Ischiropoulos H, et al. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics. 1999;103:610–618.
   PubMed Web of Science ®Google Scholar
• Mourani PM, Ivy DD, Gao D, et al. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2004;170:1006–1013.
   PubMed Web of Science ®Google Scholar
• Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev. 2017;1:CD000509.
   PubMedGoogle Scholar
• Krishnan U, Feinstein JA, Adatia I, et al. Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr. 2017;188:24–34.
   PubMed Web of Science ®Google Scholar
• Qasim A, Dasgupta S, Aly AM, et al. Sildenafil use in the treatment of bronchopulmonary dysplasia-associated pulmonary hypertension: A case series. AJP Rep. 2018;8:e219–222.
   PubMed Web of Science ®Google Scholar
• Baker CD, Abman SH, Mourani PM. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Pediatr Allergy Immunol Pulmonol. 2014;27:8–16.
   PubMed Web of Science ®Google Scholar
• Trottier-Boucher MN, Lapointe A, Malo J, et al. Sildenafil for the treatment of pulmonary arterial hypertension in infants with bronchopulmonary dysplasia. Pediatr Cardiol. 2015;36:1255–1260.
   PubMed Web of Science ®Google Scholar
• Tan K, Krishnamurthy MB, O’Heney JL, et al. Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety. Eur J Pediatr. 2015;174:1109–1115.
   PubMed Web of Science ®Google Scholar
• Sehgal A, Malikiwi A, Paul E, et al. Systemic arterial stiffness in infants with bronchopulmonary dysplasia: potential cause of systemic hypertension. J Perinatol. 2016;36:564–569.
   PubMed Web of Science ®Google Scholar
• Seghal A, Malikiwi A, Paul E, et al. A new look at bronchopulmonary dysplasia: postcapillary pathophysiology and cardiac dysfunction. Pulm Circ. 2016;6:508–515.
   PubMed Web of Science ®Google Scholar
• Ballard RA, Keller RL, Black DM, et al. Randomized trial of late surfactant treatment in ventilated preterm infants receiving inhaled nitric oxide. J Pediatr. 2016;168:23–29.
   PubMed Web of Science ®Google Scholar
• Hascoet JM, Picaud JC, Ligi I, et al. Late surfactant administration in very preterm neonates with prolonged respiratory distress and pulmonary outcome at 1 year of age: A randomized clinical trial. JAMA Pediatr. 2016;170:365–372.
   PubMed Web of Science ®Google Scholar
• Greenough A, Pahuja A. Updates on functional characterization of bronchopulmonary dysplasia - the contribution of lung function testing. Front Med (Lausanne). 2015;2:35.
   PubMed Web of Science ®Google Scholar
• Fok TF. Adjunctive pharmacotherapy in neonates with respiratory failure. Semin Fetal Neonatal Med. 2009;14:49–55.
   PubMed Web of Science ®Google Scholar
• Barrington KJ, Fortin-Pellerin E, Pennaforte T. Fluid restriction for treatment of preterm infants with chronic lung disease. Cochrane Database Syst Rev. 2017;2:CD005389.
   PubMedGoogle Scholar
• Johnson AK, Lynch N, Newberry D, et al. Impact of diuretic therapy in the treatment of bronchopulmonary dysplasia and acute kidney injury in the neonatal population. Adv Neonatal Care. 2017;17:337–346.
   PubMed Web of Science ®Google Scholar
• Stewart A, Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011;9:CD001453.
   Google Scholar
• Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011;9:CD001817.
   Google Scholar
• Pacifici GM. Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants. Paediatr Drugs. 2012;14:233–246.
   PubMed Web of Science ®Google Scholar
• Stewart AL, Brion LP. Routine use of diuretics in very-low birth-weight infants in the absence of supporting evidence. J Perinatol. 2011;31:633–634.
   PubMed Web of Science ®Google Scholar
• Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2006;3:CD001694.
   Google Scholar
• Garcia-Garcia ML, Gonzalez-Carrasco E, Quevedo S, et al. Clinical and virological characteristics of early and moderate preterm infants readmitted with viral respiratory infections. Pediatr Infect Dis J. 2015;34:693–699.
   PubMed Web of Science ®Google Scholar
• Paes B, Fauroux B, Figueras-Aloy J, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with chronic lung disease. Infect Dis Ther. 2016;5:453–471.
   PubMed Web of Science ®Google Scholar
• Greenough A, Alexander J, Boit P, et al. School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants. Thorax. 2009;64:490–495.
   PubMed Web of Science ®Google Scholar
• Drysdale SB, Alcazar-Paris M, Wilson T, et al. Rhinovirus infection and healthcare utilisation in prematurely born infants. Eur Respir J. 2013;42:1029–1036.
   PubMed Web of Science ®Google Scholar
• Pignotti MS, Carmela Leo M, Pugi A, et al. Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease. Pediatr Pulmonol. 2016;51:1088–1096.
   PubMed Web of Science ®Google Scholar
• Prais D, Kaplan E, Klinger G, et al. Short- and long-term pulmonary outcome of palivizumab in children born extremely prematurely. Chest. 2016;149:801–808.
   PubMed Web of Science ®Google Scholar
• van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med. 2009;180:1131–1142.
   PubMed Web of Science ®Google Scholar
• Antunes MA, Laffey JG, Pelosi P, et al. Mesenchymal stem cell trials for pulmonary diseases. J Cell Biochem. 2014;115:1023–1032.
   PubMed Web of Science ®Google Scholar
• Batsali AK, Kastrinaki MC, Papadaki HA, et al. Mesenchymal stem cells derived from Wharton’s Jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther. 2013;8:144–155.
   PubMed Web of Science ®Google Scholar
• Simones AA, Beisang DJ, Panoskaltsis-Mortari A, et al. Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: a clinical review. Pediatr Res. 2018;83:308–317.
   PubMed Web of Science ®Google Scholar
• Pierro M, Ionescu L, Montemurro T, et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax. 2013;68:475–484.
   PubMed Web of Science ®Google Scholar
• Aslam M, Baveja R, Liang OD, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med. 2009;180:1122–1130.
   PubMed Web of Science ®Google Scholar
• Augustine S, Avey MT, Harrison B, et al. Mesenchymal stromal cell therapy in bronchopulmonary dysplasia: systematic review and meta-analysis of preclinical studies. Stem Cells Transl Med. 2017;6:2079–2093.
   PubMed Web of Science ®Google Scholar
• Lim R, Malhotra A, Tan J, et al. First-in-human administration of allogeneic amnion cells in premature infants with bronchopulmonary dysplasia: a safety study. Stem Cells Transl Med. 2018;7:628–635.
   PubMed Web of Science ®Google Scholar
• Chang YS, Ahn SY, Yoo HS, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr. 2014;164:966–972.
   PubMed Web of Science ®Google Scholar
• Ahn SY, Chang YS, Kim JH, et al. Two-year follow-up outcomes of premature infants enrolled in the phase i trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr. 2017;185:49–54.
   PubMed Web of Science ®Google Scholar
• Wuchter P, Bieback K, Schrezenmeier H, et al. Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy. 2015;17:128–139.
   PubMed Web of Science ®Google Scholar
• Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010;5:e10088.
   PubMed Web of Science ®Google Scholar
• Gazdic M, Volarevic V, Arsenijevic N, et al. Mesenchymal stem cells: a friend or foe in immune-mediated diseases. Stem Cell Rev. 2015;11:280–287.
   PubMed Web of Science ®Google Scholar
• Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7:e47559.
   PubMed Web of Science ®Google Scholar
• Solling C. Organ-protective and immunomodulatory effects of erythropoietin–an update on recent clinical trials. Basic Clin Pharmacol Toxicol. 2012;110:113–121.
   PubMed Web of Science ®Google Scholar
• Luan Y, Zhang L, Chao S, et al. Mesenchymal stem cells in combination with erythropoietin repair hyperoxia-induced alveoli dysplasia injury in neonatal mice via inhibition of TGF-beta1 signaling. Oncotarget. 2016;7:47082–47094.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Sun C, Wang J, et al. Timing of erythropoietin modified mesenchymal stromal cell transplantation for the treatment of experimental bronchopulmonary dysplasia. J Cell Mol Med. 2018;22:5759–5763.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gao S, Yan Y, et al. Aerosolized deferoxamine administration in mouse model of bronchopulmonary dysplasia improve pulmonary development. Am J Transl Res. 2018;10:325–332.
   PubMed Web of Science ®Google Scholar